Close menu




September 22nd, 2022 | 10:25 CEST

Moderna, BrainChip Holdings, Infineon - And the winner is?

  • chips
  • AI
  • Technology
Photo credits: pixabay.com

For many years now, the Boston Consulting Group (BCG) has been selecting the 50 most innovative companies in the world. A few days ago, the hit list was published for the sixteenth time. The top ranks are occupied by Apple, Microsoft, Amazon, Alphabet and Tesla. German companies are only found with Siemens from rank 20. Innovations play an important role for investors because they enable competitive advantages, which sooner or later translates into rising share prices. But global companies are not always the only ones to be considered; it is often lucrative to look at the second tier.

time to read: 2 minutes | Author: Carsten Mainitz
ISIN: MODERNA INC. DL-_0001 | US60770K1079 , BRAINCHIP HOLDINGS LTD | AU000000BRN8 , INFINEON TECH.AG NA O.N. | DE0006231004

Table of contents:


    Moderna - At the end?

    The US biotechnology company focuses on the research and development of therapeutics and vaccines against cancer, infectious, autoimmune and cardiovascular diseases. Moderna is one of a small group of Corona vaccine manufacturers worldwide that received a windfall from the pandemic. The Company is ranked 7th in BCG's list of the world's most innovative companies - impressive.

    Moderna earned USD 13.3 billion in the past fiscal year, or USD 28.3 per share! For the current fiscal year, analysts expect a slight drop in earnings to USD 26.4 per share. The share is thus listed with a P/E ratio of only 5. All in all, the experts are optimistic about the stock and believe it has an upside potential of 66% over the next 12 months.

    Recently, however, the share came under pressure because of statements by US President Joe Biden. Biden had recently declared an official end to the Corona pandemic. Since this position probably reflected more wishful thinking than reality, the shares are recovering. Even if the vaccine boom is waning, it should not be forgotten that Moderna is active in many other fields.

    BrainChip Holdings - Unique

    The Australians are the world's first commercial manufacturer of neuromorphic AI hardware. The processor, called "Akida," features ultra-low power consumption, high performance, and a combination of neuromorphic design principles and advanced machine learning algorithms. The use of neuromorphic architecture, a type of artificial intelligence inspired by the biology of the human brain, makes all the difference.

    Experts rank this as the most efficient solution ever produced. The very property of independent learning opens up many fields of application that will be important in the future - the Internet of Things, autonomous driving and robotics are among them. The Company is still operating at a loss, but commercial production is continuously picking up speed strongly, with the mass market as the next target.

    Most recently, BrainChip shone by being accepted into global semiconductor giant ARM's AI Partner Program. The ecosystem of hardware and software specialists, which is designed to enable developers to create the next generation of AI solutions, forms another building block in market penetration. The Company is currently valued at the equivalent of EUR 1 billion. Analysts see great potential and believe the stock has a further upside of 83% on average.

    Infineon - Better than the competition

    The danger of an intensifying technology dispute between the USA and China is currently weighing on the prices of chip manufacturers. This also includes the shares of the former Siemens subsidiary. As one of the world's leading suppliers of semiconductor solutions, the Group recently benefited from a strong automotive business, the weak euro and an advantageous price mix.

    This constellation helped the chipmaker to exceed market expectations in the third quarter, just as it had done in the previous two quarters. This clearly sets the Germans apart positively from competitor Nvidia. In the last quarter, Nvidia missed the sales expectations of stock analysts and set the mood of the stock market for continued weak business.


    Innovations, products, and solutions based on them form the basis for business success and rising share prices. That is what investors should focus on. Moderna and Infineon are good vehicles for those who want to invest in large corporations. Things get particularly interesting in the second tier. Here BrainChip Holdings stands out. The Australians have great price potential with their AI chips.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Armin Schulz on October 4th, 2022 | 10:58 CEST

    JinkoSolar, TubeSolar, Encavis - Shares for the energy turnaround

    • agritech
    • renewableenergies
    • Technology

    The phase-out of fossil energy generation is a done deal in Germany, but there is still a long way to go. Germany's share of renewable energies in electricity generation was 42.4% in 2021. However, this covered only 19.7% of Germany's energy consumption. Since the flare-up of the Ukraine crisis, the expansion of renewable energies is to be accelerated. A balanced mix is essential. Spring and summer are the main times for solar power, while in fall and winter, when the days are shorter, wind power is the primary source of electricity. If we want to achieve the 2030 targets, a massive expansion is essential. Today we take a look at three renewable energy companies.

    Read

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read